BioSpace News Archive

Australian life sciences company, QBiotics Group Limited (QBiotics) is today announcing the publication[1] of positive results from a first in-human Phase I clinical trial of its anticancer pharmaceutical, tigilanol tiglate (EBC-46) in EBioMedicine, a peer-reviewed translational biomedical research journal by The Lancet.

Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the Company will participate in the 38th Annual J.P. Morgan Healthcare Conference.

Masimo (NASDAQ: MASI) announced today that in a multicenter study recently published in the Journal of Clinical Monitoring and Computing, researchers at three institutions – Loma Linda University in California (LLU), the University of California at Irvine (UCI), and Mayo Clinic in Jacksonville, Florida (MCF) – evaluated the trend accuracy of three hemoglobin (Hb) monitoring methods, including noninvasive, continuous Masimo SpHb®.1

NeuroPace, Inc. today announced that new data from a multicenter, real-world clinical study of the RNS System has demonstrated outcomes not previously seen with other neuromodulation therapies for focal epilepsy.

Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), today announced it has entered into a strategic commercial supply agreement with CarThera® for the use of Lantheus’ microbubbles in combination with SonoCloud®, a proprietary implantable device in development for the treatment of recurrent glioblastoma (rGBM)

HitGen Inc. (“HitGen”) is pleased to announce that the company has entered into a strategic collaboration with Janssen Biotech, Inc. (“Janssen”), one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to design and build novel DNA-encoded libraries (“DELs”) to discover unique small molecule assets

ArQule, Inc. announced final results from the phase 1 study for ARQ 531, an orally bioavailable, potent and reversible dual inhibitor of both wild type and C481S-mutant Bruton’s tyrosine kinase in patients with relapsed or refractory hematologic malignancies at the American Society of Hematology 2019 Annual Meeting & Exposition in Orlando, Florida.

Interim data show that patients with CLL achieved overall best objective response rate of 85% with progression-free survival of 100%

A biosensor diagnostic company based in New York, GBS Inc. is commercializing the patent-protected Saliva Glucose Biosensor in the Asia Pacific region, where there are more people living with diabetes than anywhere else in the world.

Predictive Oncology Inc. announces updates on the commercialization of its CancerQuest 2020 initiative.